Brief: IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA

Imunon

25/11/2024 13:24

Nov 25 (Reuters) - Imunon Inc  IMNN.O :
    * IMUNON ANNOUNCES RESULTS FROM ITS END-OF-PHASE 2 MEETING
WITH
THE FDA FOR ITS LEAD IMNN-001 CLINICAL PROGRAM IN ADVANCED
OVARIAN CANCER
    * IMUNON INC - IMNN-001 TREATMENT WELL TOLERATED WITH NO
SERIOUS
ADVERSE EVENTS
    * IMUNON INC - TO INITIATE 500-PATIENT PHASE 3 TRIAL IN Q1
2025
    * IMUNON INC - ANNOUNCES FDA SUPPORT FOR PHASE 3 STUDY OF
IMNN-001

Source text:  ID:nGNXVZpFL 
Further company coverage:  IMNN.O 

 ((Reuters.Briefs@thomsonreuters.com;))